GH Stock Summary and Trading Ideas (Guardant Health | NASDAQ:GH)

Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company's main franchises are Guardant360 for genomic profiling of tumors, Reveal for molecular residual disease testing, and Shield for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.

Guardant Health trades on the NASDAQ stock market under the symbol GH.

As of October 13, 2026, GH stock price declined to $162.09 with 1,229,152 million shares trading.

GH has a beta of 0.71, meaning it tends to be less sensitive to market movements. GH has a correlation of 0.02 to the broad based SPY ETF.

GH has a market cap of $21.75 billion. This is considered a Large Cap stock.

Last quarter Guardant Health reported $335 million in Revenue and -$.42 earnings per share. This beat revenue expectation by $20 million and exceeded earnings estimates by $.04.

In the last 3 years, GH traded as high as $191.05 and as low as $15.81.

The top ETF exchange traded funds that GH belongs to (by Net Assets): VTI, VB, VBK, VXF, IWP.

GH has outperformed the market in the last year with a return of +162.6%, while the SPY ETF gained +18.5%. However, in the most recent history, GH shares have underperformed the stock market with its stock returning +2.3% in the last 3 month period and -8.8% for the last 2 week period, while SPY has returned +4.1% and +1.8%, respectively.

GH support price is $157.71 and resistance is $167.87 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that GH shares will trade within this expected range on the day.